Studying Obesity and Breast Cancer Risk
October 29, 2018
Kristy A. Brown, Ph.D., is Assistant Professor of Biochemistry in Medicine at Weill Cornell Medicine. Her work aims to determine how adipose tissue can impact cancer cells, as well as the normal mammary gland, to explain why obese women are more likely to develop breast cancer and die from the disease.
We hope you enjoy learning more about Dr. Brown’s work.
Please tell us about your background and provide an overview of your work.
A Conversation with EIPM's Rohit Chandwani, M.D.
October 26, 2018
A surgeon-scientist, Dr. Chandwani is also Principal Investigator of the Laboratory of Cancer Epigenetics at Weill Cornell Medical College, where he studies the epigenetic dysregulation of pancreatic and liver cancer.
We hope you enjoy learning more about Dr. Chandwani’s work.
Please provide a brief overview of your background and work.
Next-Gen Sequencing in Precision Medicine
October 23, 2018
At the Englander Institute for Precision Medicine (EIPM), we use genomic information to help provide the right treatment to the right patient at the right time. This information is often generated for oncology patients using Next Generation Sequencing (NGS) to quickly and accurately sequence many genes at once.
Dr. Peter Martin, Chief of the Lymphoma Program
October 16, 2018
Earlier this year WCM was selected by the Leukemia and Lymphoma Society as the only medical institution in New York and one of the two sites nationwide to receive a highly competitive grant to improve therapies for mantle cell lymphoma (MCL) patients.
Spotlight on Dr. Dolores Lamb
September 5, 2018
As Vice Chair for Research in the Department of Urology and Director of the Center for Reproductive Genomics, Dr. Lamb maintains an active presence in both the academic and research communities at Weill Cornell Medicine.
Her passion for research will be evident to all who meet her, “Each new day in the lab has truly been an exciting adventure and advanced our understanding not only of the causes of these birth defects, but also other associated health conditions for these affected individuals.”
EIPM and ICB Team Translates AI Benefits to In-Vitro Fertilization
August 24, 2018
In addition to advancing cancer research, a team of EIPM and Institute for Computational Biomedicine (ICB) scientists have successfully applied AI to improve embryology and in-vitro fertilization (IVF).
2018 EIPM Summer Internship Highlights
August 20, 2018
With genomic education at the forefront of Weill Cornell Medicine’s mission to care, discover and teach, the Englander Institute for Precision Medicine (EIPM) invited gifted high school and college students to join our multidisciplinary team this summer as part of the inaugural 2018 EIPM Internship Program. While students came from diverse backgrounds, geographic locations, age ranges and skill sets, they left with a shared understanding and appreciation for the critically important role of technology and precision medicine in patient care.
Patient Derived Prostate Cancer Organoids to Advance Precision Medicine
June 28, 2018
A small amount of tumor cells taken from a patient are embedded in an extracellular matrix and grown in the laboratory. As the cells develop in vitro, they form three-dimensional structures that mimic the patient’s disease. These structures, called tumor organoids, are at the forefront of cancer research – they allow researchers to test new drugs and investigate new treatments with a personalized, targeted approach.
Spotlight on Dr. Jan Krumsiek
May 8, 2018
Welcome, Dr. Jan Krumsiek, Assistant Professor of Physiology and Biophysics in the Department of Physiology and Biophysics, and the newest member of the Englander Institute for Precision Medicine. Previously a visiting fellow in the Leandro Cerchietti lab, Dr. Krumsiek answered a few quick questions to elaborate on his experience and interests.
Please provide a brief overview of your work before Weill Cornell Medicine.
Hyperion Module added to EIPM Arsenal
March 30, 2018
At the Englander Institute for Precision Medicine (EIPM) we strive to be at the forefront of translational research. In conjunction with the WorldQuant Initiative for Quantitative Prediction, we are delighted to announce our latest technological gem: a CyTOF coupled to the Hyperion module – one of only 30 of its kind currently in use and the only one in the NYC.